Video

Dr. Hwang on Treatment Selection in Metastatic Castration-Sensitive Prostate Cancer

Author(s):

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

In addition to volume of disease, toxicity should be taken into account when deciding between hormonal therapy and chemotherapy, as chemotherapy and hormonal therapies have different safety profiles, says Hwang. With docetaxel, some patients need to be monitored for infections, which can potentially be fatal. Additionally, patients who receive docetaxel should be healthier than those who are given one of the hormonal therapies.

Among the hormonal therapies, enzalutamide (Xtandi) can result in seizures. Patients on apalutamide (Erleada) or enzalutamide should be monitored for potential central nervous system toxicity, adds Hwang. Patients on abiraterone acetate (Zytiga) should also be monitored for cardiac toxicity and liver function, as this treatment can lead to elevated liver enzymes. Darolutamide (Nubeqa), one of the newer antiandrogens, may not have that toxicity; however, more mature data are needed to confirm the agent’s safety profile.

The patient’s comorbidities and overall health are also factored into the treatment decision. If financial toxicity is also a concern, the length of therapy can weigh into the decision as well, concludes Hwang.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity